{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:10:34Z","timestamp":1785323434342,"version":"3.55.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clml.2023.02.004","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T22:17:07Z","timestamp":1677104227000},"page":"e195-e212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review"],"prefix":"10.1016","volume":"23","author":[{"given":"Jasneet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Sudha","family":"Valisekka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8066-4584","authenticated-orcid":false,"given":"Maha","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushyami Satya","family":"Bandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyukta","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibuzor Joseph","family":"Onwughalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himani","family":"Mongia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.02.004_bib0001","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2023.02.004_bib0002","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2023.02.004_bib0003","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2023.02.004_bib0004","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0005","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0006","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2023.02.004_bib0008","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0009","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3816\/CLML.2011.n.011","article-title":"IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering waldenstr\u00f6m's macroglobulinemia (SWM)","volume":"11","author":"Kyle","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0010","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jdv.13847","article-title":"Monoclonal gammopathy of cutaneous significance: review of a relevant concept","volume":"31","author":"Lipsker","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"13","key":"10.1016\/j.clml.2023.02.004_bib0012","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0013","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0014","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0002-9343(98)00080-1","article-title":"Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly","volume":"104","author":"Cohen","year":"1998","journal-title":"Am J Med."},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0015","first-page":"785","article-title":"Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting","volume":"116","author":"Singh","year":"1990","journal-title":"J Lab Clin Med"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0016","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.clml.2023.02.004_bib0017","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0018","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City","volume":"82","author":"Iwanaga","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.clml.2023.02.004_bib0019","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12185-011-0995-4","article-title":"Prevalence of monoclonal gammopathy of undetermined significance in Thailand","volume":"95","author":"Watanaboonyongcharoen","year":"2012","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2023.02.004_bib0020","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.clml.2018.06.005","article-title":"Prevalence of monoclonal gammopathy of undetermined significance in India-a hospital-based study","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0021","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/bjh.16487","article-title":"The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions","volume":"189","author":"Atkin","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0022","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-021-04400-7","article-title":"Risk factors for monoclonal gammopathy of undetermined significance: a systematic review","volume":"100","author":"Castaneda-Avila","year":"2021","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0023","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"suppl 8","key":"10.1016\/j.clml.2023.02.004_bib0024","article-title":"Trends in survival and costs among U.S. patients with multiple myeloma","volume":"35","author":"Maiese","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.02.004_bib0025","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0026","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/1055-9965.EPI-14-1145","article-title":"A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium","volume":"24","author":"Andreotti","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0027","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1096-8652(199607)52:3<217::AID-AJH15>3.0.CO;2-C","article-title":"Risk of monoclonal gammopathy of undetermined significance: a case-referent study","volume":"52","author":"Pasqualetti","year":"1996","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.clml.2023.02.004_bib0028","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","article-title":"Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study","volume":"1","author":"Thordardottir","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.02.004_bib0029","doi-asserted-by":"crossref","first-page":"j477","DOI":"10.1136\/bmj.j477","article-title":"Adiposity and cancer at major anatomical sites: umbrella review of the literature","volume":"356","author":"Kyrgiou","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0030","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/1055-9965.EPI-16-0762-T","article-title":"Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the International Multiple Myeloma Consortium (IMMC)","volume":"26","author":"Birmann","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0031","doi-asserted-by":"crossref","first-page":"djw264","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study","volume":"109","author":"Chang","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0032","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S2352-3026(14)00037-4","article-title":"Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study","volume":"2","author":"Chang","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.clml.2023.02.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6615684","article-title":"Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?","volume":"2021","author":"da Cunha J\u00fanior","year":"2021","journal-title":"Adv Hematol"},{"issue":"7","key":"10.1016\/j.clml.2023.02.004_bib0034","first-page":"372","article-title":"Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma","volume":"14","author":"Dezube","year":"2004","journal-title":"AIDS Read"},{"issue":"17","key":"10.1016\/j.clml.2023.02.004_bib0035","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1001\/jama.1986.03380170059011","article-title":"Oligoclonal bands in serum protein electrophoretograms of individuals with human immunodeficiency virus antibodies","volume":"256","author":"Kouns","year":"1986","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0036","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ndt\/11.12.2461","article-title":"Monoclonal gammopathy after intense induction immunosuppression in renal transplant patients","volume":"11","author":"Passweg","year":"1996","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.clml.2023.02.004_bib0037","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamaoncol.2015.2938","article-title":"Agent orange exposure and monoclonal gammopathy of undetermined significance: an operation ranch hand veteran cohort study","volume":"1","author":"Landgren","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.02.004_bib0038","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ajh.2830380216","article-title":"Occupational risk for hematological malignancies","volume":"38","author":"Pasqualetti","year":"1991","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2023.02.004_bib0039","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2008-05-159665","article-title":"Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors","volume":"113","author":"Iwanaga","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaoncol.2018.0509","article-title":"Multiple myeloma and its precursor disease among firefighters exposed to the world trade center disaster","volume":"4","author":"Landgren","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0041","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98803-1","article-title":"Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study","volume":"11","author":"Hornung","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.clml.2023.02.004_bib0042","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.3390\/ijms20112822","article-title":"Lymphocyte subsets and inflammatory cytokines of monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"20","author":"Allegra","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0043","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-021-04400-7","article-title":"Risk factors for monoclonal gammopathy of undetermined significance: a systematic review","volume":"100","author":"Castaneda-Avila","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0044","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1096-8652(199607)52:3<217::AID-AJH15>3.0.CO;2-C","article-title":"Risk of monoclonal gammopathy of undetermined significance: a case-referent study","volume":"52","author":"Pasqualetti","year":"1996","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.clml.2023.02.004_bib0045","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1182\/blood-2011-04-347559","article-title":"Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study","volume":"118","author":"Lindqvist","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.02.004_bib0046","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.004_bib0047","doi-asserted-by":"crossref","first-page":"34","DOI":"10.12703\/r\/11-34","article-title":"Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond","volume":"11","author":"Abeykoon","year":"2022","journal-title":"Fac Rev"},{"issue":"8","key":"10.1016\/j.clml.2023.02.004_bib0048","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41375-018-0030-3","article-title":"Prognostic significance of interphase fish in monoclonal gammopathy of undetermined significance","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.clml.2023.02.004_bib0049","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-07-0031","article-title":"Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance, and monosomy 13 is restricted to these hyperdiploid patients","volume":"13","author":"Brousseau","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clml.2023.02.004_bib0050","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.V90.9.3682","article-title":"Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition","volume":"90","author":"Zandecki","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0051","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11914-018-0479-z","article-title":"Contributions of the bone microenvironment to monoclonal gammopathy of undetermined significance pathogenesis","volume":"16","author":"G\u00e1mez","year":"2018","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0052","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2010.11.003","article-title":"Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma","volume":"48","author":"Zingone","year":"2011","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0053","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/cncr.11100","article-title":"Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia","volume":"97","author":"Ana","year":"2003","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.clml.2023.02.004_bib0054","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0056","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.02.004_bib0057","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IGM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.02.004_bib0058","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V94.8.2583.420a05_2583_2589","article-title":"Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"94","author":"Avet-Loiseau","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0059","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1309\/4W8E-8F4K-BHUP-UBE7","article-title":"The (11;14)(Q13;Q32) translocation in multiple myeloma","volume":"113","author":"Hoyer","year":"2000","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V89.3.965","article-title":"Detection of cyclin D1 (bcl-1, prad1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in T(11; 14)(Q13; q32)-bearing B-cell malignancies and\/or mantle cell lymphoma","volume":"89","author":"Uchimaru","year":"1997","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2023.02.004_bib0061","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood.2019846782","article-title":"Monoclonal gammopathy of undetermined significance","volume":"133","author":"Mouhieddine","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.02.004_bib0062","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.02.004_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/209670","article-title":"Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience","volume":"2014","author":"Smetana","year":"2014","journal-title":"Biomed Res Int"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0064","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/leu.2012.128","article-title":"SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status","volume":"26","author":"L\u00f3pez-Corral","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1309\/6U88-357U-UKJ5-YPT3","article-title":"Cytogenetic findings in lymphoplasmacytic lymphoma \/waldenstr\u00f6m macroglobulinemia","volume":"116","author":"Mansoor","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.clml.2023.02.004_bib0066","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1038\/sj.leu.2401909","article-title":"Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance","volume":"14","author":"K\u00f6nigsberg","year":"2000","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0067","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","article-title":"Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0068","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IGM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0069","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.02.004_bib0070","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IGH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0071","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3324\/haematol.2013.093500","article-title":"Circulating serum micrornas as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"99","author":"Kubiczkova","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0072","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.clml.2023.02.004_bib0073","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0074","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/hematology.2020000122","article-title":"Monoclonal gammopathies of clinical significance","volume":"2020","author":"Dispenzieri","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol."},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0076","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.ajkd.2003.09.020","article-title":"Long-term outcome of renal transplantation in light-chain deposition disease","volume":"43","author":"Leung","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0077","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.01.028","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft","volume":"94","author":"Said","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0078","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.mayocp.2019.12.033","article-title":"Monoclonal gammopathy of undetermined significance: indications for prediagnostic testing, subsequent diagnoses, and follow-up practice at Mayo clinic","volume":"95","author":"Ravindran","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"5-6","key":"10.1016\/j.clml.2023.02.004_bib0079","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/07853890.2013.801562","article-title":"Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians","volume":"45","author":"Caers","year":"2013","journal-title":"Ann Med"},{"issue":"20","key":"10.1016\/j.clml.2023.02.004_bib0080","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2023.02.004_bib0081","first-page":"243","article-title":"Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options","volume":"77","author":"Amaador","year":"2019","journal-title":"Neth J Med"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0082","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3390\/cancers12061554","article-title":"Monoclonal gammopathy of undetermined significance (MGUS)-not so asymptomatic after all","volume":"12","author":"Lomas","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clml.2023.02.004_bib0083","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00319857","article-title":"The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings","volume":"238","author":"Yeung","year":"1991","journal-title":"J Neurol"},{"issue":"1-2","key":"10.1016\/j.clml.2023.02.004_bib0084","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2014.01.012","article-title":"Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy","volume":"268","author":"Stork","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"8","key":"10.1016\/j.clml.2023.02.004_bib0085","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.clml.2023.02.004_bib0086","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1468-1331.2011.03380.x","article-title":"Neuropathy and paraproteins: review of a complex association","volume":"18","author":"Rajabally","year":"2011","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.clml.2023.02.004_bib0087","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.26155","article-title":"The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance","volume":"96","author":"Castillo","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0088","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0b013e3181ccc6b9","article-title":"Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study","volume":"74","author":"Niermeijer","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.clml.2023.02.004_bib0089","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cger.2021.01.004","article-title":"Paraproteinemias and peripheral nerve disease","volume":"37","author":"Leavell","year":"2021","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.clml.2023.02.004_bib0090","article-title":"Recurrence of paraproteinemic crystalline keratopathy after corneal transplantation: a case of monoclonal gammopathy of ocular significance","volume":"19","author":"Nobacht","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"50","key":"10.1016\/j.clml.2023.02.004_bib0091","doi-asserted-by":"crossref","first-page":"e8649","DOI":"10.1097\/MD.0000000000008649","article-title":"Paraproteinemic keratopathy in monoclonal gammopathy of undetermined significance treated with primary keratoprosthesis: case report, histopathologic findings, and world literature review","volume":"96","author":"Chiang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0092","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0002-9394(78)90230-1","article-title":"Analysis of corneal crystalline deposits in multiple myeloma","volume":"86","author":"Klintworth","year":"1978","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0093","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/ICO.0b013e31818200f4","article-title":"Classic lattice corneal dystrophy associated with monoclonal gammopathy after exclusion of a TGFBI mutation","volume":"28","author":"Kamal","year":"2009","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0094","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3341\/kjo.2011.25.3.202","article-title":"A case of crystalline keratopathy in monoclonal gammopathy of undetermined significance (MGUS)","volume":"25","author":"Koo","year":"2011","journal-title":"Korean J Ophthalmol"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcjo.2014.04.011","article-title":"A series of 4 cases of distinct keratopathy secondary to dysproteinemia: immunotactoid keratopathy","volume":"49","author":"Hall","year":"2014","journal-title":"Can J Ophthalmol"},{"issue":"9","key":"10.1016\/j.clml.2023.02.004_bib0096","doi-asserted-by":"crossref","first-page":"938","DOI":"10.4103\/0301-4738.143933","article-title":"In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: report of two cases","volume":"62","author":"Kocabeyoglu","year":"2014","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0097","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clml.2013.09.012","article-title":"Subepithelial corneal immunoglobulin deposition as a manifestation of multiple myeloma: a case report and literature review","volume":"14","author":"Wang","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2023.02.004_bib0098","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ophtha.2015.05.029","article-title":"Paraproteinemic Keratopathy: the expanding diversity of clinical and pathologic manifestations","volume":"122","author":"Milman","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0099","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/ICO.0b013e31821ddd0c","article-title":"Chameleon-like appearance of immunotactoid keratopathy","volume":"31","author":"Lisch","year":"2012","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.clml.2023.02.004_bib0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000514375","article-title":"Diagnosing paraproteinemic keratopathy: a case report","volume":"12","author":"Mok","year":"2021","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.clml.2023.02.004_bib0101","article-title":"Monoclonal gammopathy of \"ocular\" significance","volume":"15","author":"Karakus","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0102","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-022-00661-1","article-title":"Cutaneous manifestations of monoclonal gammopathy","volume":"12","author":"Claveau","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0103","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jdv.13847","article-title":"Monoclonal gammopathy of cutaneous significance: review of a relevant concept","volume":"31","author":"Lipsker","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0104","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/ddg.14751","article-title":"Monoclonal gammopathy with cutaneous significance treated successfully with rituximab","volume":"20","author":"Koutra","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"20","key":"10.1016\/j.clml.2023.02.004_bib0105","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.3390\/cancers13205131","article-title":"Fern\u00e1ndez de Larrea C. Treatment of Patients with Monoclonal Gammopathy of Clinical Significance","volume":"13","author":"Moreno","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0106","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjh.13196","article-title":"Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases","volume":"168","author":"Harel","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","article-title":"Cryoglobulinaemia","volume":"4","author":"Roccatello","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0109","doi-asserted-by":"crossref","first-page":"567","DOI":"10.23736\/S0392-0488.20.06692-4","article-title":"Schnitzler syndrome: the paradigm of an acquired adult-onset auto-inflammatory disease","volume":"155","author":"Gusdorf","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.clml.2023.02.004_bib0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11926-017-0673-5","article-title":"Schnitzler syndrome: a Review","volume":"19","author":"Gusdorf","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"suppl","key":"10.1016\/j.clml.2023.02.004_bib0111","first-page":"S27","article-title":"A patient with urticarial lesions, recurrent fever, and IgM-type monoclonal gammopathy","volume":"31","author":"Kecelj \u017dgank","year":"2022","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0112","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/all.12129","article-title":"Schnitzler's syndrome: diagnosis, treatment, and follow-up","volume":"68","author":"Simon","year":"2013","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0113","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamadermatol.2017.5978","article-title":"The association of age with clinical presentation and comorbidities of pyoderma gangrenosum","volume":"154","author":"Ashchyan","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0114","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaad.2015.07.031","article-title":"The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: association with IgA isotype and inflammatRory profile","volume":"73","author":"Szalat","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/11595240-000000000-00000","article-title":"Etiology and management of pyoderma gangrenosum: a comprehensive review","volume":"13","author":"Ahronowitz","year":"2012","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0116","first-page":"506","volume":"38","author":"Zhao","year":"2022","journal-title":"Zhonghua Shao Shang Za Zhi"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0117","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum\u2014a guide to diagnosis and management","volume":"19","author":"George","year":"2019","journal-title":"Clin Med (Lond)"},{"issue":"11","key":"10.1016\/j.clml.2023.02.004_bib0118","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00105-018-4257-8","article-title":"Skleromyx\u00f6dem [Scleromyxedema]","volume":"69","author":"Neufeld","year":"2018","journal-title":"Hautarzt"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaad.2013.01.007","article-title":"Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients","volume":"69","author":"Rongioletti","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0120","first-page":"1449","article-title":"Scleromyxedema","volume":"18","author":"Hoffmann","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0121","first-page":"13","article-title":"An unusual presentation of scleromyxedema as inflammatory myopathy","volume":"38","author":"Vysakha","year":"2019","journal-title":"Acta Myol"},{"key":"10.1016\/j.clml.2023.02.004_bib0122","article-title":"Generalized acquired cutis laxa associated with monoclonal gammopathy of dermatological significance","volume":"2020","author":"Shalhout","year":"2020","journal-title":"Case Rep Dermatol Med"},{"issue":"11","key":"10.1016\/j.clml.2023.02.004_bib0123","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2014.725","article-title":"Acquired cutis laxa associated with heavy chain deposition disease involving dermal elastic fibers","volume":"150","author":"O'Malley","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0124","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2018.03.039","article-title":"Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature","volume":"79","author":"Jachiet","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.clml.2023.02.004_bib0125","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2008.01181.x","article-title":"Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy","volume":"82","author":"Fern\u00e1ndez de Larrea","year":"2009","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0126","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2023.02.004_bib0127","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0128","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0129","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","article-title":"Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0131","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","article-title":"Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management","volume":"92","author":"Chaudhry","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2023.02.004_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117335","article-title":"Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience","volume":"423","author":"Mat\u00e0","year":"2021","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clml.2023.02.004_bib0133","series-title":"StatPearls","article-title":"Monoclonal Gammopathy of Undetermined Significance","author":"Kaseb","year":"2022"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0134","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cger.2015.08.012","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma in older adults","volume":"32","author":"Guerard","year":"2016","journal-title":"Clin Geriatr Med"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0135","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.6004\/jnccn.2020.7660","article-title":"Diagnosis and management of monoclonal gammopathy and smoldering multiple myeloma","volume":"18","author":"Schmidt","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"10.1016\/j.clml.2023.02.004_bib0136","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and management of monoclonal gammopathy of renal significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0137","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"R\u00f6gnvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0138","first-page":"1655","article-title":"Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma","volume":"152","author":"Ocqueteau","year":"1998","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0139","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.hoc.2014.06.005","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"28","author":"Kyle","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2023.02.004_bib0140","unstructured":"Sigurdur Y Kristinsson. Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM). ClinicalTrials.gov Identifier: NCT03327597. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03327597"},{"key":"10.1016\/j.clml.2023.02.004_bib0141","unstructured":"Irene Ghobrial, MD. Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE). ClinicalTrials.gov Identifier: NCT03689595. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03689595"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0142","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.ackd.2012.07.006","article-title":"Monoclonal gammopathy of undetermined significance: an update for nephrologists","volume":"19","author":"Parry","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.02.004_bib0143","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ijlh.12504","article-title":"Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"38","author":"van de Donk","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0144","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/hon.2345","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management","volume":"35","author":"Maciocia","year":"2017","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.02.004_bib0145","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/ndt\/gfy259","article-title":"The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance","volume":"34","author":"Batko","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0146","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41375-018-0202-1","article-title":"Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance","volume":"32","author":"Merz","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0147","doi-asserted-by":"crossref","first-page":"e23233","DOI":"10.1002\/jcla.23233","article-title":"Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"34","author":"Li","year":"2020","journal-title":"J Clin Lab Anal"},{"issue":"12","key":"10.1016\/j.clml.2023.02.004_bib0148","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0149","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clml.2017.02.028","article-title":"Waldenstr\u00f6m macroglobulinemia: review of pathogenesis and management","volume":"17","author":"Yun","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2023.02.004_bib0150","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/14656561003769874","article-title":"Amyloidosis and POEMS syndrome","volume":"11","author":"Chee","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.clml.2023.02.004_bib0151","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5858\/arpa.2012-0034-RS","article-title":"Lymphoplasmacytic lymphoma and Waldenstr\u00f6m macroglobulinemia","volume":"137","author":"Naderi","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0152","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-10-1822","article-title":"From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention","volume":"17","author":"Landgren","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.clml.2023.02.004_bib0153","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.3390\/cancers14215247","article-title":"Monoclonal gammopathies of clinical significance: a critical appraisal","volume":"14","author":"R\u00edos-Tamayo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0154","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.clml.2023.02.004_bib0155","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2023.02.004_bib0156","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10027","key":"10.1016\/j.clml.2023.02.004_bib0157","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.clml.2023.02.004_bib0158","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2023.02.004_bib0159","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clml.2015.12.007","article-title":"Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study","volume":"16","author":"Berdeja","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"10.1016\/j.clml.2023.02.004_bib0161","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.02.004_bib0162","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05366.x","article-title":"Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure\u2013a retrospective analysis and recommendations for dose adjustment","volume":"128","author":"Carlson","year":"2005","journal-title":"Br J Haematol"},{"issue":"7-8","key":"10.1016\/j.clml.2023.02.004_bib0163","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1081\/CNV-120005903","article-title":"The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study","volume":"20","author":"Lichtman","year":"2002","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.clml.2023.02.004_bib0164","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.10213","article-title":"Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis","volume":"71","author":"Jillella","year":"2002","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.clml.2023.02.004_bib0165","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clml.2023.02.004_bib0166","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2023.02.004_bib0167","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2023.02.004_bib0168","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.004_bib0169","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41590-018-0205-0","article-title":"Author correction: the twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat Immunol."},{"key":"10.1016\/j.clml.2023.02.004_bib0170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2023.02.004_bib0171","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the united kingdom medical research council trials between 1980 and 2002\u2014medical research council adult leukaemia working party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.02.004_bib0172","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1182\/blood.V114.22.1852.1852","article-title":"Lack of response to vaccination in MGUS and stable myeloma","volume":"114","author":"Prabhala","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.02.004_bib0173","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2017.02.025","article-title":"Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial","volume":"17","author":"Branagan","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clml.2023.02.004_bib0174","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1002\/cam4.2253","article-title":"Response to pneumococcal vaccination in multiple myeloma","volume":"8","author":"Renaud","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-0383","article-title":"Vaccination of oncology patients: an effective tool and an opportunity not to be missed","volume":"17","author":"Kotton","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2023.02.004_bib0176","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2023.02.004_bib0177","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","article-title":"Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis","volume":"36","author":"Veronese","year":"2017","journal-title":"J Bone Miner Metab."},{"key":"10.1016\/j.clml.2023.02.004_bib0178","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.02.004_bib0179","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.02.004_bib0180","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma network","volume":"99","author":"Van De Donk","year":"2014","journal-title":"Haematology"},{"key":"10.1016\/j.clml.2023.02.004_bib0181","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3816\/CLM.2007.n.027","article-title":"Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders","volume":"7","author":"Auwerda","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2023.02.004_bib0182","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clml.2023.02.004_bib0183","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0184","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2023.02.004_bib0185","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.02.004_bib0186","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2023.02.004_bib0187","first-page":"192","article-title":"Emerging options for combination therapy in multiple myeloma","volume":"16","author":"Rossi","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2023.02.004_bib0188","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2023.02.004_bib0189","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/tri.12497","article-title":"Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge","volume":"28","author":"Nambirajan","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.clml.2023.02.004_bib0190","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2215\/CJN.08640811","article-title":"Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution","volume":"7","author":"Nasr","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.clml.2023.02.004_bib0191","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.02.004_bib0192","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2013.34","article-title":"Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients","volume":"27","author":"Roeker","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.02.004_bib0193","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-142149","article-title":"Malignant progression of monoclonal gammopathy of undetermined significance: a systematic review and meta-analysis","volume":"136","author":"Low","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.02.004_bib0194","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","article-title":"Monoclonal gammopathy of undetermined significance: a consensus statement","volume":"150","author":"Berenson","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:37Z","timestamp":1761871297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":194,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2152265023000605"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.02.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}